

Jennifer L Mcquade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541323/publications.pdf>

Version: 2024-02-01

58
papers

4,945
citations

186265

28
h-index

175258

52
g-index

61
all docs

61
docs citations

61
times ranked

8393
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983.	4.1	12
2	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43
3	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2046-2049.e3.	0.7	8
4	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
5	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
6	Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. , 2021, 9, e002058.		30
7	Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. <i>Case Reports in Oncology</i> , 2021, 14, 224-231.	0.7	2
8	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
9	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
10	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq0 0 0 rgBT /Overlock 10	4.4	1
11	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
12	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177.	0.7	12
13	The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 500-511.	4.1	58
14	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. <i>Cancers</i> , 2021, 13, 5301.	3.7	7
15	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
16	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
17	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, e602-e605.	3.7	35
18	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	2.8	11

#	ARTICLE	IF	CITATIONS
19	The Great Debate at “Immunotherapy Bridge”, Naples, December 5, 2019. , 2020, 8, e000921.		3
20	Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head and Neck, 2020, 42, E35-E42.	2.0	9
21	Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer, 2020, 126, 3708-3718.	4.1	33
22	Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Current Oncology Reports, 2020, 22, 74.	4.0	34
23	Gut Microbiome Modulates Response to Cancer Immunotherapy. Digestive Diseases and Sciences, 2020, 65, 885-896.	2.3	38
24	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
25	Patient Nutrition: An Overlooked Yet Emerging Variable in the Precision Oncology Equation. Journal of Immunotherapy and Precision Oncology, 2020, 3, 108-112.	1.4	0
26	Nutrition and Cancer in the Microbiome Era. Trends in Cancer, 2019, 5, 521-524.	7.4	17
27	Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. Current Oncology Reports, 2019, 21, 72.	4.0	29
28	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clinical Cancer Research, 2019, 25, 6429-6442.	7.0	61
29	Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncology, The, 2019, 20, e77-e91.	10.7	249
30	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	9.4	231
31	Integrating Storytelling into a Communication Skills Teaching Program for Medical Oncology Fellows. Journal of Cancer Education, 2019, 34, 1198-1203.	1.3	12
32	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i> -Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	7.0	57
33	A Preexisting Rare <i>PIK3CA</i> E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling. Cancer Discovery, 2018, 8, 556-567.	9.4	55
34	Estrogen returns to the stage in melanoma. Pigment Cell and Melanoma Research, 2018, 31, 554-555.	3.3	4
35	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
36	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	10.7	486

#	ARTICLE	IF	CITATIONS
37	Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 11-30.	3.3	149
38	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	2.6	31
39	Body-mass index and metastatic melanoma outcomes – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e227-e228.	10.7	3
40	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , The, 2018, 19, e376.	10.7	8
41	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253
42	Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. <i>Cancer</i> , 2017, 123, 1989-1997.	4.1	43
43	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1792-1795.	0.7	40
44	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N and ^{on} V ⁶⁰⁰ mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	4.1	36
45	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
46	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>OncolImmunology</i> , 2017, 6, e1361097.	4.6	50
47	Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial. <i>Psycho-Oncology</i> , 2017, 26, 1936-1943.	2.3	60
48	Integrative Oncology Outpatient Consultations: Long-Term Effects on Patient-Reported Symptoms and Quality of Life. <i>Journal of Cancer</i> , 2017, 8, 1640-1646.	2.5	7
49	Integrative Oncology Physician Consultations at a Comprehensive Cancer Center: Analysis of Demographic, Clinical and Patient Reported Outcomes. <i>Journal of Cancer</i> , 2017, 8, 395-402.	2.5	39
50	A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 604-608.	1.2	17
51	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
52	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
53	Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. <i>PLoS ONE</i> , 2016, 11, e0154985.	2.5	22
54	Acupuncture for Xerostomia in Patients with Cancer: An Update. <i>Medical Acupuncture</i> , 2015, 27, 158-167.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Systematic review of acupuncture to control hot flashes in cancer patients. <i>Cancer</i> , 2015, 121, 3948-3958.	4.1	34
56	Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition. <i>Molecular and Cellular Oncology</i> , 2015, 2, e991610.	0.7	15
57	Acupuncture for Symptom Management in Cancer Care: an Update. <i>Current Oncology Reports</i> , 2014, 16, 418.	4.0	32
58	Systematic Review of Acupuncture in Cancer Care: A Synthesis of the Evidence. <i>Journal of Clinical Oncology</i> , 2013, 31, 952-960.	1.6	277